## PHAFMA DEKT $p$ fe

## FINANCIAL STATEMENT FOR HALF YEAR 2021

 STATEMENT OF COMPREHENSIVE INCOME
(Note: the number of shares as at March.'21, 217million shares)

## PHARTMA <br> DEKT ple

## FINANCIAL STATEMENT FOR HALF YEAR 2021

 STATEMENT OF FINANCIAL POSITIONProperty, plant and equipment
Deferred TaxAssets
Investment property Intangible Assets
Investments accounted for using the equity method
Financial assets
Non-current asset held for sale and disposal groups

## Total Non Current Assets

Inventories
Debtors and Other Receivables
Cash and cash equivalents
Total Current Assets

Trade and Other Payables
Current Financial liabilities
Current Tax Liabilities

## Total Current Liabilities

Non-Current Financial liabilities
Provisions (Employee Benefits)
Deferred Tax Liabilities
Total Non-Current Liabilities
Working Capital
Net Assets

Non Controlling Interest
Attributable to Owners of the Company

| As At Jun |
| ---: |
| $\mathbf{2 0 2 1}$ |
| N'000 |
| 1,643,387 |
| - |
| - |
|  |
|  |

1,643,387
$\overline{1,663,711}$
$-1.22 \% \overline{1,733,933}$
194,917

| 174,102 | $11.95 \%$ | 293,330 |
| ---: | :---: | :---: | :---: |
| 70,835 | $1.96 \%$ | 163,976 |
| $\mathbf{1 0 8 , 4 0 8}$ | $-66 \%$ | 6,163 |
| $\mathbf{3 5 3 , 3 4 5}$ | $-14 \%$ | $\mathbf{4 6 3 , 4 6 9}$ |

615,877

| 674,519 | $-8.69 \%$ | 500,822 |
| ---: | ---: | ---: |
| 13,336 | $-3 \%$ | 15,000 |
| 124,602 | $0 \%$ | 123,450 |
| $\mathbf{8 1 2 , 4 5 7}$ | $-7.26 \%$ | $\mathbf{6 3 9 , 0 4 2}$ |


| 197,643 | 200,261 | $-1.3 \%$ | 228,816 |
| ---: | ---: | ---: | ---: |
| $\mathbf{1 8 , 0 7 1}$ | 18,071 | $0 \%$ | 18,071 |
| $\mathbf{2 1 5 , 7 1 4}$ | $\mathbf{2 1 8 , 3 3 2}$ | $-1.2 \%$ | $\mathbf{2 4 6 , 8 8 7}$ |
| $(449,675)$ | $(459,112)$ | $-2 \%$ | $(175,573)$ |
| $\mathbf{9 7 7 , 9 9 8}$ | $\mathbf{9 8 6 , 2 6 7}$ | $-0.84 \%$ | $\mathbf{1 , 3 1 1 , 4 7 3}$ |

## PHAPMA DEMO PLE

## FINANCIAL STATEMENT FOR HALF YEAR 2021

## STATEMENT OF CHANGE IN EQUITY

|  | Share | Capital | Revaluation | Retained | Total |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | Capital | Reserve | Surplus | Earnings | Equity |
| Balance as at Beginning of the Prior Year | 108,466 | 380,009 | 1,365,223 | $(542,225)$ | 1,311,473 |
| Changes in Equity Current year: |  |  |  |  |  |
| Refund on Right Issue |  | - |  |  | - |
| Revaluation Surplus (net of tax) |  |  | - |  | - |
| Dividend Paid | - | - | - |  |  |
| Total Comprehensive Income | - | - | - | $(325,206)$ | $(325,206)$ |
| Balance as at End of the Prior Year | 108,466 | 380,009 | 1,365,223 | $(867,431)$ | 986,267 |
| Changes in Equity Current year: |  |  |  |  |  |
| Movement during the year |  | - |  | - | - |
| Revaluation Surplus (net of tax) |  |  |  |  | - |
| Interim Dividend Paid |  |  |  | - | - |
| Total Comprehensive Income | - | - | - | $(8,269)$ | $(8,269)$ |
| Balance as at End of the Period | 108,466 | 380,009 | 1,365,223 | (875,700) | 977,998 |

## PHARMA DEMD ple

## FINANCIAL STATEMENT FOR HALF YEAR 2021

## STATEMENT OF CASH FLOW

| Cash Flow from Operating Activities |  |  |  |
| :---: | :---: | :---: | :---: |
| Operating Cash Flow before Working Capital Changes | $(57,280)$ | 106,804 | -153.6\% |
| Net Cash Generated from Operating Activities | $(58,255)$ | 104,592 | -155.7\% |
| Net Cash provided (used) by investing activities | $(13,262)$ | (713) | 1760\% |
| Cash Flow from Financing Activities | (336) | $(1,664)$ | -78\% |
| Net Increase/Decrease Cash and Cash Equivalent | $(71,853)$ | 102,215 | -170\% |
| Cash Equivalent Beginning of the Year | 108,408 | 6,163 | 1659\% |
| Effect of exchange rate movement on cash balances | 109 | 30 | 267\% |
| Total Cash at the end of the period | 36,664 | 108,408 | -66.2\% |

